🟢 Intellia Therapeutics Inc is trading 5.84% up today as it extends gains from positive CRISPR trial data

Intellia Therapeutics Inc is trading at $15.40 (+5.84%) today, extending a sharp upward move sparked by recent positive CRISPR trial data.

• The stock continues to digest volatility following a June 15 surge and subsequent profit-taking on June 16.
• Trading volume remains active as investors reassess the company's late-stage pipeline and projected 2027 commercial path.